Proteomedix gains patent for Proclarix in China

Proteomedix has been granted a patent in China for its prostate cancer test, Proclarix. According to a press release from the company based in Schlieren in the canton of Zurich, the China National Intellectual Property Administration has granted a patent for Proteomedix’s application entitled “Method of detecting proteins in human samples and uses of such methods”. According to the press release, this covers its main product, Proclarix.

Ralph Schiess, CSO and Co-Founder of Proteomedix, commented: “The granting of the patent in China further strengthens our intellectual property position for our lead product Proclarix and highlights our commitment to innovation of biomarkers for prostate cancer diagnosis and prognosis.”

Patents have already been received for Proclarix in Europe, Japan, South Korea, and just recently in July for the USA. The press release goes on to state that the issued patents and published studies confirm Proclarix’s potential and support the ongoing observational studies, which are investigating the effects of the IVD (in-vitro diagnostic) test on improving prostate cancer diagnosis.

According to statements by Proteomedix, Proclarix is an innovative blood-based test. It should put an end to unnecessary biopsies as the test first determines whether cancer is in fact present at all or at most in a minor form. Proteomedix has presented positive study results for Proclarix. The test has been able to detect clinically significant prostate cancer with a high sensitivity of more than 90 percent.

Proteomedix is a spin-off from the Swiss Federal Institute of Technology Zurich (ETH). It is based at the Bio-Technopark Schlieren-Zürich.